Vizient, Inc. represents the combined strengths of the organizations formerly known as VHA Inc., University HealthSystem Consortium, Novation and MedAssets' Spend and Clinical Resource Management. Since 2003, nearly 2200 new and innovative products and technologies have been submitted through the Vizient Innovative Technology program. Vizient works with member-led councils and task forces to identify and review potentially innovative products. If it is determined that a product is innovative, a contract may be awarded outside of Vizient's competitive bid cycle.

Globally, breast cancer is an ever-growing problem and the well documented limitations of current methods for diagnosis have been significantly challenged, especially in dense breast tissue. Developing a non-compressional breast imaging device that provides a real 3D imaging capability at low radiation doses was the primary focus in the development of the Koning dedicated breast CT. Advanced CT imaging has been the gold standard for head, neck, chest, and abdomen imaging for decades. Now, those same advanced imaging benefits and diagnostic capabilities have been brought to breast with the KBCT.


Koning Corporation's KBCT was FDA-approved in January 2015, making it the first dedicated breast CT imaging system to launch in the North American marketplace. A unique modality, the KBCT provides 3D isotropic multi-planar images of the breast - without compression and with high dose efficiency within the 10-second scan. Another major performance advantage of the KBCT technology is the ability to perform 3D image-guided biopsies as part of the diagnostic scanning workflow when needed. Combining multiple applications into one device provides economic benefit when compared to the add on or standalone biopsy devices commonly in use. KBCT 3D guided biopsy can cut the dose by half compared to add-on or prone stereotactic biopsy systems.

Back to HCB News

Business Affairs Homepage